Anetumab Ravtansine
- CAS No.
- 1375258-01-7
- Chemical Name:
- Anetumab Ravtansine
- Synonyms
- Anetumab Ravtansine;Anetumab ravtansine (ADC)
- CBNumber:
- CB18080889
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
| FDA UNII | M170940PMI |
|---|---|
| NCI Drug Dictionary | anetumab ravtansine |
Anetumab Ravtansine Chemical Properties,Uses,Production
Uses
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models[1].
in vivo
Anetumab ravtansine (10 mg/kg; i.v.) is localized specifically to mesothelin-positive tumors and inhibits tumor growth in both subcutaneous and orthotopic xenograft models[1].
| Animal Model: | Subcutaneous and orthotopic xenograft models: MIA PaCa, HT29, OVCAR-3, NCI-H226 and so on (NMRI nu/nu mice: 18-25 g, 7-10 weeks old)[1] |
| Dosage: | 2.7 mg/kg (0.05 mg/kg DM4), 10.6 mg/kg (0.2 mg/kg DM4) |
| Administration: | MF-T, or S-methyl-DM4 on days 5, 8, and 12 (mice implanted with MIA PaCa or HT29 meso cells); on days 33, 36, and 40 (OVCAR-3); on days 78, 81, 84, 127, 130, and 133 (NCI-H226); on days 15, 18, and 22 (OVCAR-3- s-05 orthotopic); on days 7, 10, and 13 (HT29 titration); Q3Dx3 starting on day 0 (PAXF736); Q3Dx3 starting on day 29 (OVCAR6719); or Q4Dx3 starting on day 34 (Meso7212) after tumor cell inoculation. |
| Result: | Resulted in complete tumor eradication at 10.6 mg/kg (0.2 mg/kg DM4), lasting for at least 17 weeks following the final treatment. Eradicated tumors in 5 out of 6 animals in the MIA PaCa-2/meso model rather than in HT-29/ meso model at 2.7 mg/kg (0.05 mg/kg DM4). |
References
[1] Golfier S, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014 Jun;13(6):1537-48. DOI:10.1158/1535-7163.MCT-13-0926
Anetumab Ravtansine Preparation Products And Raw materials
Raw materials
Preparation Products
Anetumab Ravtansine Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 6762 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
| Wuhan Peptide Core Biotechnology Co., Ltd | 027-65317797 13667154760 | 1096814016@qq.com | China | 10711 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 0731-13823398 15111215862 | 313359644@qq.com | China | 4161 | 58 |
| bioleaper | 4000880777 17585207275 | guojing@bioleaper.com | China | 5616 | 58 |
| Olix (Shanghai) Pharmaceutical Technology Co., Ltd | 17316404525 17316404525 | 209533805@qq.com | China | 9763 | 58 |
| Atagenix Laboratories | 027-87008169 17762441161 | info@atagenix.com | China | 10001 | 58 |
| Biosynth Biological Technology (Suzhou) Co Ltd | 51288865780 | sales@biosynth.com | China | 6051 | 58 |
| Selleck Chemicals | 400-668-6834 | info@selleck.cn | China | 6071 | 58 |
